- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03335956
CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)
A Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAD and MAD of CORT125281 in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
- Drug: Prednisone 25mg, fasted
- Drug: Placebo oral capsule, fasted
- Drug: CORT125281, 40mg, fasted
- Drug: CORT125281, 120mg, fasted
- Drug: CORT125281, 360mg, fasted
- Drug: CORT125281, 720mg, fasted
- Drug: Placebo oral capsule, fed
- Drug: Prednisone 25mg, fed
- Drug: CORT125281, 360mg, fed
- Drug: Placebo oral capsule
- Drug: Placebo oral capsule
- Drug: Placebo oral capsule
- Drug: CORT125281, 360mg
- Drug: CORT125281, 360mg
- Drug: Pioglitazone 15mg Tablet
- Drug: CORT125281, 120mg
- Drug: CORT125281, 180mg
- Drug: CORT125281, 240mg
Detailed Description
Separate single-and multiple-ascending dose (SAD and MAD) parts will be conducted. Throughout each part of the study, safety, pharmacological (PD) and PK effects will be assessed. Safety and tolerability will be assessed using adverse event (AE) monitoring, measurement of vital signs, recording 12-lead electrocardiogram (ECG), physical examination and clinical laboratory safety tests. Blood samples will be collected at intervals for assay of plasma concentration of CORT125281 and CORT125324.
The SAD part of the study is double-blind, randomized and placebo-controlled with respect to CORT125281. Two cohorts, each of 9 subjects, will receive three sequential single doses of the investigational medicinal product (IMP), either CORT125281 at the assigned dose level or placebo, in a partial within-subject crossover manner. The starting dose is CORT125281, 40 mg; the rules for determining later doses are detailed within the protocol. The PD effects of CORT125281 will be examined by testing its ability to ameliorate the pharmacological effects of a concomitantly administered dose of prednisone.
The MAD part of the study will be double-blind, randomized, placebo-controlled and parallel-group with respect to CORT125281. Up to four cohorts of 8 subjects, randomized so that 6 receive CORT125281 and 2 receive placebo, will participate in the study, so that up to four dose levels of CORT125281 are studied in total. An exploratory assessment will be made of the effect of repeated doses of CORT125281 on exposure to pioglitazone, probe substrate for CYP2C8. Each subject will be admitted on Day-1 for baseline assessments. On Day1, subjects will receive a single oral dose of pioglitazone, 15mg. From Day3 to Day16 (14 days), subjects will be dosed daily with IMP (CORT125281 at the selected dose or placebo). On Day13, subjects will receive a second dose of pioglitazone, 15 mg.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom
- Hammersmith Medicines Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Give written informed consent
- If male, have undergone vasectomy, with no wish to have the procedure reversed
If female, using appropriate precautions to avoid pregnancy, defined as of nonchildbearing potential (ie, postmenopausal or permanently sterilised) or using highly effective contraception with low user-dependency
- A woman is postmenopausal if it is more than 12 months since her last menstruation, without an alternative medical cause. A concentration of FSH in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy.
- Accepted methods of permanent sterilization methods are hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
- An IUD is the only acceptable method of highly effective contraception with low user-dependency, provided that the subject has tolerated its use for at least 3 months before the first dose of study medication and undertakes not to have it removed for 1 month after the last dose.
- Be aged 18 to 65 years inclusive
- Have a BMI of 19 to 30 kg/m2, inclusive
- Be willing to comply with study restrictions as described in Section 4.6
- Be able to comply with the requirements of the entire study
- Be judged to be in good health, based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory findings
- For multiple dose cohorts, have a morning serum cortisol within the local reference range at screening and/or Day -1
- Have suitable veins for multiple venepunctures/cannulation
- Be able to swallow size 0 capsules whole
Exclusion Criteria:
- Be an employee or immediate family member of the CRU or Corcept
- Have been previously enrolled in this study
- Have multiple drug allergies, or be allergic to any of the components of study medication, its matching placebo, challenge agents or probe substrates (see Section 5.1)
- Have a condition that could be aggravated by glucocorticoid blockade (eg, asthma, any chronic inflammatory condition) or activation (eg, immunodeficiency, active infection) Subjects with inactive seasonal hay fever may be included. Subjects with childhood (aged less than 18 years) asthma may be included provided they have had no symptoms and required no treatment for at least 5 years
In the 6 calendar months before study drug administration, on average
- Have smoked more than 5 cigarettes/day
- Have consumed more than 14 units (female) or 21 units (male) of alcohol/week
- Consumed liquorice or other glycyrrhetic acid derivatives regularly, in the judgement of the Investigator
In the 3 calendar months before study drug administration
- Have donated blood or plasma in excess of 400 mL
- Have participated in another clinical trial of a new chemical entity or a prescription medicine
- Have a positive test for alcohol, smoking or drugs of abuse at screening or admission to any of the dosing sessions
Have clinically-relevant abnormal findings on vital signs, physical examination, laboratory screening tests, or 12-lead ECG, at screen and/or before first dose, including but not limited to:
- Abnormal ECG waveform morphology that would preclude accurate measurement of the QT interval
- QTcF >450 ms (from mean of 3 supine ECGs, performed at least 2 minutes apart)
- Stage 2 or higher hypertension (supine/semi-recumbent systolic blood pressure [SBP] >160 mmHg; diastolic blood pressure [DBP] >100 mmHg, based on mean of duplicate values recorded at least 2 minutes apart)
- Stage 1 hypertension (supine/semi-recumbent SBP 140-160 mmHg; DBP 90-100 mmHg, based on mean of duplicate values recorded at least 2 minutes apart) associated with indication for treatment ie, evidence of end-organ damage, diabetes or a 10 year cardiovascular risk, estimated using a standard calculator eg, QRisk2 2016 >20%
- Glomerular filtration rate, estimated using the chronic kidney disease epidemiology (collaboration) (CKD-EPI) method (eGFR; see Section 6.2.5) <60 mL/minute/1.73 m2
- Hypokalaemia (potassium below lower limit of normal)
- ALT, AST and/or gammaglutamyl transferase (GGT) >1.5 times the upper limit of normal
- Seropositive for hepatitis B, hepatitis C or human immunodeficiency viruses.
- Have any medical or social reasons for not participating in the study raised by their General Practitioner/primary care physician
- Have any other condition that might increase the risk to the individual or decrease the chance of obtaining satisfactory data, as assessed by the Investigator
- Taken any prohibited prior medication, as described in Section 4.6.3
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: SAD Part 1 Placebo Cohort 1 Period 1
|
Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered |
Experimental: SAD Part 1 Active Cohort Period 1
|
Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered
CORT125281 is supplied as capsules for oral dosing
|
Placebo Comparator: SAD Part 1 Placebo Cohort 1 Period 2
|
Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered |
Experimental: SAD Part 1 Active Cohort 1 Period 2
|
Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered
CORT125281 is supplied as capsules for oral dosing
|
Placebo Comparator: SAD Part 1 Placebo Cohort 1 Period 3
|
Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered |
Experimental: SAD Part 1 Active Cohort 1 Period 3
|
Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered
CORT125281 is supplied as capsules for oral dosing
|
Placebo Comparator: SAD Part 2 Placebo Cohort 2 Period 4
|
Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered |
Experimental: SAD Part 2 Active Cohort 2 Period 4
|
Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered
CORT125281 is supplied as capsules for oral dosing
|
Placebo Comparator: SAD Part 2 Placebo Cohort 2 Period 5
|
Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered |
Experimental: SAD Part 2 Active Cohort 2 Period 5
|
Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered
CORT125281 is supplied as capsules for oral dosing
|
Placebo Comparator: SAD Part 2 Placebo Cohort 2 Period 6
|
Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered, twice daily Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered, once daily |
Experimental: SAD Part 2 Active Cohort 2 Period 6
|
Challenge Agent, Dose and Route of Administration: Standard release 25 mg tablets, orally administered
CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal
CORT125281 is supplied as capsules for oral dosing once daily
|
Placebo Comparator: MAD Placebo Cohort 1
|
Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered, twice daily Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered, once daily Probe Substrate, Dose and Route of Administration: 15 Mg tablet, orally administered |
Experimental: MAD Active Cohort 1
|
Probe Substrate, Dose and Route of Administration: 15 Mg tablet, orally administered
CORT125281 is supplied as capsules for oral dosing once daily
|
Placebo Comparator: MAD Placebo Cohort 2
|
Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered, twice daily Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered, once daily Probe Substrate, Dose and Route of Administration: 15 Mg tablet, orally administered |
Experimental: MAD Active Cohort 2
|
Probe Substrate, Dose and Route of Administration: 15 Mg tablet, orally administered
CORT125281 is supplied as capsules for oral dosing twice daily
|
Placebo Comparator: MAD Placebo Cohort 3
|
Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered, twice daily Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered, once daily Probe Substrate, Dose and Route of Administration: 15 Mg tablet, orally administered |
Experimental: MAD Active Cohort 3
|
Probe Substrate, Dose and Route of Administration: 15 Mg tablet, orally administered
CORT125281 is supplied as capsules for oral dosing twice daily
|
Placebo Comparator: MAD Placebo Cohort 4
|
Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered twice, 12 hours apart, fasted (morning) and after evening meal Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered, twice daily Reference Therapy, Dose and Route of Administration: Placebo capsule, orally administered, once daily Probe Substrate, Dose and Route of Administration: 15 Mg tablet, orally administered |
Experimental: MAD Active Cohort 4
|
CORT125281 is supplied as capsules for oral dosing twice, 12 hours apart, fasted (morning) and after evening meal
CORT125281 is supplied as capsules for oral dosing once daily
Probe Substrate, Dose and Route of Administration: 15 Mg tablet, orally administered |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse Events (AEs)
Time Frame: SAD Cohorts Day 1 to Day 14; MAD Cohorts Day 1 to Day 30
|
SAD Cohorts Day 1 to Day 14; MAD Cohorts Day 1 to Day 30
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUCtau Pharmacokinetic (PK) parameter
Time Frame: MAD Cohorts Day 3 to 19
|
Area under the curve over a dose-interval (AUCtau)
|
MAD Cohorts Day 3 to 19
|
AUC 0-tz PK parameter
Time Frame: CORT125281/CORT125324 - SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19; Pioglitizone - MAD Cohort Day 1 to 15
|
Area under the curve from the time of dosing until the last quantifiable concentration (AUC 0-tz)
|
CORT125281/CORT125324 - SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19; Pioglitizone - MAD Cohort Day 1 to 15
|
AUC 0-infinity PK parameter
Time Frame: CORT125281/CORT125324 - SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19; Pioglitizone - MAD Cohort Day 1 to 15
|
Area under the curve from the time of dosing extrapolated to infinity (AUC 0-infinity)
|
CORT125281/CORT125324 - SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19; Pioglitizone - MAD Cohort Day 1 to 15
|
Cmax PK parameter
Time Frame: CORT125281/CORT125324 - SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19; Pioglitizone - MAD Cohort Day 1 to 15
|
Maximum concentration (Cmax)
|
CORT125281/CORT125324 - SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19; Pioglitizone - MAD Cohort Day 1 to 15
|
Cmin PK parameter
Time Frame: MAD Cohorts Day 3 to 19
|
Minimum concentration within a dose interval (Cmin)
|
MAD Cohorts Day 3 to 19
|
Tmax PK parameter
Time Frame: SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
|
Time to maximum concentration (Tmax)
|
SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
|
tlag PK parameter
Time Frame: SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
|
Latest time after dosing before the first quantifiable concentration (tlag)
|
SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
|
apparent terminal rate constant PK parameter
Time Frame: SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
|
SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
|
|
t1/2 PK parameter
Time Frame: SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
|
Apparent terminal elimination half-life (t1/2)
|
SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
|
MRT PK parameter
Time Frame: SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
|
Mean residence time (MRT)
|
SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
|
Vz/F PK parameter
Time Frame: SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
|
Apparent oral volume of distribution during the terminal elimination phase (Vz/F)
|
SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
|
CL/F PK parameter
Time Frame: SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
|
Apparent oral clearance (CL/F)
|
SAD Cohorts Day 1 to 4; MAD Cohorts Day 3 to 19
|
Observed accumulation ratio PK parameter
Time Frame: MAD Cohorts Day 3 to 19
|
MAD Cohorts Day 3 to 19
|
|
4β-OH cholesterol PK parameter
Time Frame: MAD Cohorts Day 1 to Day 17
|
4β-Hydroxycholesterol (4β-OH)
|
MAD Cohorts Day 1 to Day 17
|
Pharmacodynamics (PD) Peripheral blood neutrophil, eosinophil and lymphocyte counts
Time Frame: SAD Cohorts pre-dose through 24 hours post dose
|
SAD Cohorts pre-dose through 24 hours post dose
|
|
PD Serum osteocalcin
Time Frame: SAD Cohorts pre-dose through 24 hours post dose
|
SAD Cohorts pre-dose through 24 hours post dose
|
|
PD Pre- and postprandial blood glucose
Time Frame: SAD Cohorts Day 1, pre-dose to 6 hours post dose
|
SAD Cohorts Day 1, pre-dose to 6 hours post dose
|
|
PD Cytokines
Time Frame: SAD Cohorts Day 1, pre-dose to 24 hours post dose; MAD Cohorts Day 3 to Day 10
|
SAD Cohorts Day 1, pre-dose to 24 hours post dose; MAD Cohorts Day 3 to Day 10
|
|
PD T cell profiling by flow cytometry
Time Frame: SAD Cohorts Day 1, pre-dose to 24 hours post dose; MAD Cohorts Day 3 to Day 10
|
SAD Cohorts Day 1, pre-dose to 24 hours post dose; MAD Cohorts Day 3 to Day 10
|
|
PD Gene expression for glucocorticoid-modulated genes
Time Frame: SAD Cohorts Day 1, pre-dose to 4 hours post dose
|
SAD Cohorts Day 1, pre-dose to 4 hours post dose
|
|
PD Cortisol
Time Frame: MAD Cohorts pre-dose to Day 16
|
MAD Cohorts pre-dose to Day 16
|
|
PD ACTH
Time Frame: MAD Cohorts pre-dose to Day 16
|
Adrenocorticotropic hormone (ACTH)
|
MAD Cohorts pre-dose to Day 16
|
PD DHEA S
Time Frame: MAD Cohorts Day 3 to Day 16
|
Dehydroepiandrosterone sulphate (DHEA-S)
|
MAD Cohorts Day 3 to Day 16
|
PD androstenedione
Time Frame: MAD Cohorts Day 3 to Day 16
|
MAD Cohorts Day 3 to Day 16
|
|
PD Fasting glucose
Time Frame: MAD Cohorts Day 1 to Day 13
|
MAD Cohorts Day 1 to Day 13
|
|
PD insulin
Time Frame: MAD Cohorts Day 1 to Day 13
|
MAD Cohorts Day 1 to Day 13
|
|
PD HOMA-IR
Time Frame: MAD Cohorts Day 1 to Day 13
|
Homeostatic model assessment of insulin-resistance (HOMA-IR)
|
MAD Cohorts Day 1 to Day 13
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Stacie Shepherd, M.D., Ph.D., Corcept Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CORT125281-600
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Prednisone 25mg, fasted
-
PfizerViiV HealthcareCompleted
-
Boehringer IngelheimCompletedPsoriasisUnited States, Canada, Germany
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Not yet recruitingHealthy | Overweight and ObesityUnited States
-
Eli Lilly and CompanyCompleted
-
Hanmi Pharmaceutical Company LimitedCompletedDiabetes MellitusKorea, Republic of
-
GlaxoSmithKlineCompletedDepressive Disorder and Anxiety DisordersGermany
-
University of British ColumbiaUniversity of OtagoNot yet recruiting
-
PfizerCompletedHealthy VolunteersBelgium
-
University of TorontoCompleted
-
New York Obesity and Nutrition Research CenterColumbia University; St. Luke's-Roosevelt Hospital CenterUnknownObesityUnited States